340 related articles for article (PubMed ID: 16740975)
1. Retinoic acid as a novel medical therapy for Cushing's disease in dogs.
Castillo V; Giacomini D; Páez-Pereda M; Stalla J; Labeur M; Theodoropoulou M; Holsboer F; Grossman AB; Stalla GK; Arzt E
Endocrinology; 2006 Sep; 147(9):4438-44. PubMed ID: 16740975
[TBL] [Abstract][Full Text] [Related]
2. Potential role for retinoic acid in patients with Cushing's disease.
Pecori Giraldi F; Ambrogio AG; Andrioli M; Sanguin F; Karamouzis I; Corsello SM; Scaroni C; Arvat E; Pontecorvi A; Cavagnini F
J Clin Endocrinol Metab; 2012 Oct; 97(10):3577-83. PubMed ID: 22851491
[TBL] [Abstract][Full Text] [Related]
3. Cushing's disease in dogs: cabergoline treatment.
Castillo VA; Gómez NV; Lalia JC; Cabrera Blatter MF; García JD
Res Vet Sci; 2008 Aug; 85(1):26-34. PubMed ID: 17910968
[TBL] [Abstract][Full Text] [Related]
4. Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.
Castillo V; Theodoropoulou M; Stalla J; Gallelli MF; Cabrera-Blatter MF; Haedo MR; Labeur M; Schmid HA; Stalla GK; Arzt E
Neuroendocrinology; 2011; 94(2):124-36. PubMed ID: 21525729
[TBL] [Abstract][Full Text] [Related]
5. Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease.
Granger N; de Fornel P; Devauchelle P; Segond S; Delisle F; Rosenberg D
J Vet Intern Med; 2005; 19(1):23-8. PubMed ID: 15715043
[TBL] [Abstract][Full Text] [Related]
6. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal concentrations.
Peterson ME; Orth DN; Halmi NS; Zielinski AC; Davis DR; Chavez FT; Drucker WD
Endocrinology; 1986 Aug; 119(2):720-30. PubMed ID: 3015556
[TBL] [Abstract][Full Text] [Related]
7. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
8. Diurnal ACTH and plasma cortisol variations in healthy dogs and in those with pituitary-dependent Cushing's syndrome before and after treatment with retinoic acid.
Castillo VA; Cabrera Blatter MF; Gómez NV; Sinatra V; Gallelli MF; Ghersevich MC
Res Vet Sci; 2009 Apr; 86(2):223-9. PubMed ID: 18692856
[TBL] [Abstract][Full Text] [Related]
9. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
[TBL] [Abstract][Full Text] [Related]
10. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
11. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.
Suri D; Weiss RE
J Clin Endocrinol Metab; 2005 Mar; 90(3):1340-6. PubMed ID: 15585550
[TBL] [Abstract][Full Text] [Related]
12. FSH-producing macroadenoma associated in a patient with Cushing's disease.
Oyama K; Yamada S; Hukuhara N; Hiramatsu R; Taguchi M; Yazawa M; Matsuda A; Ohmura E; Imai Y
Neuro Endocrinol Lett; 2006 Dec; 27(6):733-6. PubMed ID: 17187002
[TBL] [Abstract][Full Text] [Related]
13. Cushing's disease associated with both pituitary microadenoma and corticotroph hyperplasia.
Haap M; Gallwitz B; Meyermann R; Mittelbronn M
Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):289-93. PubMed ID: 19085700
[TBL] [Abstract][Full Text] [Related]
14. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.
Pecori Giraldi F; Scaroni C; Arvat E; Martin M; Giordano R; Albiger N; Leao AA; Picu A; Mantero F; Cavagnini F
Clin Endocrinol (Oxf); 2006 Feb; 64(2):219-24. PubMed ID: 16430724
[TBL] [Abstract][Full Text] [Related]
15. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome.
Assié G; Bahurel H; Coste J; Silvera S; Kujas M; Dugué MA; Karray F; Dousset B; Bertherat J; Legmann P; Bertagna X
J Clin Endocrinol Metab; 2007 Jan; 92(1):172-9. PubMed ID: 17062771
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
17. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
18. Early post-operative ACTH and cortisol as predictors of remission in Cushing's disease.
Acebes JJ; Martino J; Masuet C; Montanya E; Soler J
Acta Neurochir (Wien); 2007; 149(5):471-7; discussion 477-9. PubMed ID: 17406780
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
Woo YS; Isidori AM; Wat WZ; Kaltsas GA; Afshar F; Sabin I; Jenkins PJ; Monson JP; Besser GM; Grossman AB
J Clin Endocrinol Metab; 2005 Aug; 90(8):4963-9. PubMed ID: 15886242
[TBL] [Abstract][Full Text] [Related]
20. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease.
van den Bosch OF; Stades AM; Zelissen PM
Clin Endocrinol (Oxf); 2014 Feb; 80(2):184-90. PubMed ID: 23841642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
